Phospho-Tyrosine Hydroxylase (Ser31) Antibody (Rabbit mAb) [G15H6]

Application: Reactivity: Mouse, Rat

Usage Information

Dilution
WB1:1000 IP1:30 IHC1:6000 FCM1:500

Application
WB, IP, IHC, FCM

Reactivity
Mouse, Rat

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
59 kDa 60 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
Phospho-Tyrosine Hydroxylase (Ser31) Antibody (Rabbit mAb) [G15H6] detects endogenous levels of total Tyrosine Hydroxylase protein only when it is phosphorylated at Ser31.

Clone
G15H6

Synonym(s)
Tyrosine 3-monooxygenase, Tyrosine 3-hydroxylase, TH, Th

Background
Tyrosine hydroxylase belongs to the aromatic amino acid hydroxylase family, alongside phenylalanine hydroxylase and the tryptophan hydroxylases, and catalyzes the rate-limiting step of catecholamine biosynthesis, converting L-tyrosine to L-DOPA using tetrahydrobiopterin and molecular oxygen as cofactors. The enzyme assembles as a tetramer, with each subunit built from three domains: an N-terminal regulatory domain containing a structured ACT-fold segment preceded by a flexible N-terminal tail, a central catalytic domain housing the active-site iron and substrate-binding pocket, and a C-terminal oligomerization domain responsible for tetramer assembly. Ser31 sits within the flexible N-terminal tail of this regulatory domain, one of four serine residues subject to phosphorylation alongside Ser8, Ser19, and Ser40, and Ser31 is phosphorylated specifically by ERK1 and ERK2, with in vitro kinetic analysis showing that ERK2 phosphorylates Ser31-containing peptides from tyrosine hydroxylase with catalytic efficiency several-fold higher than a standard myelin basic protein-derived ERK substrate peptide, establishing Ser31 as a preferred physiological ERK substrate rather than an incidental phosphorylation site. Phosphorylation of the regulatory domain, including at Ser31, is proposed to displace this domain from a position obstructing the catalytic active site, and phosphatases subsequently return the domain to its inactivating conformation, giving phosphorylation-dephosphorylation cycling at this site direct control over enzymatic access to substrate. Ser31 phosphorylation increases tyrosine hydroxylase catalytic activity, though to a substantially lesser extent than phosphorylation at Ser40, and Ser31 phosphorylation additionally participates in a hierarchical regulatory relationship with Ser40: prior Ser31 phosphorylation markedly increases subsequent Ser40 phosphorylation, while Ser40 phosphorylation has no reciprocal effect on Ser31, and pharmacological inhibition of ERK activation reduces both Ser31 phosphorylation and basal Ser40 phosphorylation levels, indicating that ERK-driven Ser31 phosphorylation facilitates Ser40 rephosphorylation as a mechanism for sustaining tyrosine hydroxylase activation ahead of dopamine-induced enzyme inhibition. In dopaminergic and noradrenergic neurons, depolarization and calcium influx activate ERK signaling, driving Ser31 phosphorylation as part of the depolarization-dependent activation of tyrosine hydroxylase and catecholamine output, and in vivo studies of morphine withdrawal and of dopamine recovery following nigrostriatal lesion link ERK-dependent Ser31 phosphorylation directly to sustained noradrenaline and dopamine signaling under conditions of altered neuronal activity.

Background

Tyrosine hydroxylase belongs to the aromatic amino acid hydroxylase family, alongside phenylalanine hydroxylase and the tryptophan hydroxylases, and catalyzes the rate-limiting step of catecholamine biosynthesis, converting L-tyrosine to L-DOPA using tetrahydrobiopterin and molecular oxygen as cofactors. The enzyme assembles as a tetramer, with each subunit built from three domains: an N-terminal regulatory domain containing a structured ACT-fold segment preceded by a flexible N-terminal tail, a central catalytic domain housing the active-site iron and substrate-binding pocket, and a C-terminal oligomerization domain responsible for tetramer assembly. Ser31 sits within the flexible N-terminal tail of this regulatory domain, one of four serine residues subject to phosphorylation alongside Ser8, Ser19, and Ser40, and Ser31 is phosphorylated specifically by ERK1 and ERK2, with in vitro kinetic analysis showing that ERK2 phosphorylates Ser31-containing peptides from tyrosine hydroxylase with catalytic efficiency several-fold higher than a standard myelin basic protein-derived ERK substrate peptide, establishing Ser31 as a preferred physiological ERK substrate rather than an incidental phosphorylation site. Phosphorylation of the regulatory domain, including at Ser31, is proposed to displace this domain from a position obstructing the catalytic active site, and phosphatases subsequently return the domain to its inactivating conformation, giving phosphorylation-dephosphorylation cycling at this site direct control over enzymatic access to substrate. Ser31 phosphorylation increases tyrosine hydroxylase catalytic activity, though to a substantially lesser extent than phosphorylation at Ser40, and Ser31 phosphorylation additionally participates in a hierarchical regulatory relationship with Ser40: prior Ser31 phosphorylation markedly increases subsequent Ser40 phosphorylation, while Ser40 phosphorylation has no reciprocal effect on Ser31, and pharmacological inhibition of ERK activation reduces both Ser31 phosphorylation and basal Ser40 phosphorylation levels, indicating that ERK-driven Ser31 phosphorylation facilitates Ser40 rephosphorylation as a mechanism for sustaining tyrosine hydroxylase activation ahead of dopamine-induced enzyme inhibition. In dopaminergic and noradrenergic neurons, depolarization and calcium influx activate ERK signaling, driving Ser31 phosphorylation as part of the depolarization-dependent activation of tyrosine hydroxylase and catecholamine output, and in vivo studies of morphine withdrawal and of dopamine recovery following nigrostriatal lesion link ERK-dependent Ser31 phosphorylation directly to sustained noradrenaline and dopamine signaling under conditions of altered neuronal activity.

References
https://pubmed.ncbi.nlm.nih.gov/21176768/ https://pubmed.ncbi.nlm.nih.gov/37776259/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%